Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge.

This strategy focuses on optimized biologics that provide meaningful differentiation in crowded therapeutic landscapes. Apogee's year end financials show a company laying down roots for the long haul.

Targeting T-cell activation has transformed the therapeutic landscape for patients with immune-mediated diseases. Next-generation treatments will target balance over suppression to achieve their goal.

Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, ...

Intellect replaced emotion as the focus of therapy. For decades, CBT has dominated the therapeutic landscape. Research has supported its apparent ability to treat a variety of psychological ...

In 2025, the therapeutic landscape for advanced prostate cancer in Germany is marked by remarkable progress—ranging from radioligand therapy to precision imaging and immunotherapy. This article ...

Image Caption: Key signaling pathways in anaplastic thyroid cancer. Different pathways are labeled in different colors, and different components in the same pathway are portrayed in the same color ...